IBA and PET Pharm Bio sign contract to install a Cyclone® IKON in Taiwan

Core Insights - IBA has signed a contract with PET Pharm Bio to establish a PET and SPECT isotopes production center in Taipei, Taiwan, utilizing the Cyclone IKON cyclotron technology [1][4] - The new facility will produce novel radiopharmaceuticals for theranostics and targeted therapies, including isotopes such as Germanium-68, Iodine-123, Thallium-201, Zirconium-89, and Copper-64 [3][4] - The Cyclone IKON solution is expected to enhance PET Pharm Bio's capabilities in the radiopharmaceutical market, positioning it as a leader in Taiwan and Southeast Asia [4] Company Overview - PET Pharm Bio, established in 2011, focuses on the research, development, and production of radiopharmaceuticals, aiming to improve patient health and advance precision diagnosis and treatment in nuclear medicine [6] - IBA is recognized as the world leader in particle accelerator technology, providing equipment and services in proton therapy, industrial sterilization, and radiopharmaceuticals, with a workforce of approximately 2,100 employees [7] Financial Aspects - The typical end-user price for a Cyclone IKON solution ranges from EUR 10 million to EUR 15 million, depending on options and associated equipment [3]